Pharmaceutical clinical research and regulation: an impact evaluation of public policy
Roberto Ippoliti and
POLIS Working Papers from Institute of Public Policy and Public Choice - POLIS
Taking human experimentation into account, this work aims at estimating a policy designed to reduce transaction costs that are related to the protection system of patients' rights, with both a normative and positive approach. On the one hand, considering a sample of European countries as counterfactual, an empirical analysis is performed in order to estimate the impact of a national law aimed at harmonizing the procedure to obtain opinions on clinical trials. On the other hand, an alternative law, which might be able to favor the exchange between pharmaceutical companies and patients, is proposed. Assuming that the competitiveness of the national protection system is based on the time required to obtain an authorization for an experimental activity, pharmaceutical clinical research should be positively affected by a reform of the current law. However, there is also evidence of a wasted opportunity to optimize the governance of the national protection system.
Keywords: Transaction costs; International Review Boards (IRB); Medical researcher; Research subject; Clinical research (search for similar items in EconPapers)
JEL-codes: I18 L51 (search for similar items in EconPapers)
Pages: 26 pages
New Economics Papers: this item is included in nep-hea
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
https://drive.google.com/file/d/1VdGbSns8LiXcZoGzO ... eO0/view?usp=sharing (application/pdf)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:uca:ucapdv:165
Access Statistics for this paper
More papers in POLIS Working Papers from Institute of Public Policy and Public Choice - POLIS
Bibliographic data for series maintained by Lucia Padovani ().